~~<i id='1B780D252A'><strike id='1B780D252A'><tt id='1B780D252A'><pre id='1B780D252A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

entertainment

author：knowledge 2025-10-01 23:31:30 - browse：9945

Sarepta Therapeutics said Monday afternoon that its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large clinical trial — likely a major disappointment for patients and doctors who have been desperately awaiting the treatment for years.

The company said all patients in the study improved and that secondary measurements indicated the drug was having an effect. Nevertheless, the results are likely to raise questions about whether the Food and Drug Administration will expand access to the medicine.

Trading in Sarepta shares was halted at $107 with the release of the study results.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Advances in CAR

leisure time

hotspot

knowledge

Dr.MonicaBertagnollispeaksduringavisitfromfirstladyJillBidentotheUniversityofCaliforniaSanFranciscoH

WSS

The system is set up to fail children with medical complexity

How generative AI is inspiring dreams of a health data revolution

Covid hospitalizations on the rise, Humana says

Cigna wins case to block Amy Bricker's move to CVS

What drug price negotiations mean for Medicare Part D

ALS patient reclaims some autonomy thanks to wearable 'robot'

Wikipedia

entertainment

leisure time

Drug repurposing or repositioning? The language matters

How generative AI is inspiring dreams of a health data revolution

Heart attack and stroke risk calculators need revising

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Continuity nursing helped my family in our darkest PICU moments

Teladoc has a new CEO, but challenges remain the same

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Affirmative action in medical school literally saved lives

'Essentially witchcraft:' A former naturopath takes on the field

leisure time

Advances in CAR

What drug price negotiations mean for Medicare Part D

Statins may not be needed by millions of people, study suggests

Illumina names Agilent executive as new CEO

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

House transparency, PBM reform bill gains bipartisan support

hotspot

hotspot

hotspot

knowledge